Background And Aims: The decreasing Helicobacter pylori eradication rate and the increasing antibiotic resistance trend are of great concern. Therefore, new and effective therapies are needed for H. pylori infection. We conducted a systematic review and meta-analysis to assess the efficacy and safety of semisynthetic tetracycline regimens in H. pylori treatment.

Methods: PubMed, EMBASE, and the Cochrane library were searched. The outcome indicators were the eradication rate, risk ratio (RR, ie, the risk of the semisynthetic tetracycline regimen relative to the control), and 95% confidence interval (95% CI). Controls were patients undergoing any other treatment without semisynthetic tetracycline.

Results: Twenty-three studies with 5240 participants were included. The eradication rates of triple regimens with semisynthetic tetracyclines in most studies were less than 70% in both the intention-to-treat (ITT) and the per-protocol (PP) analyses. The pooled eradication rates of quadruple therapies with doxycycline and controls were 95% and 84% in the PP analyses, respectively. The pooled RR associated with efficacy in the quadruple therapy with doxycycline group compared with the control group was 1.12 (95% CI: 1.04-1.20) in the PP analysis. The pooled RR of side effects in the quadruple therapy with doxycycline group compared with the control group was 1.01 (95% CI: 0.65-1.55).

Conclusion: Seven-day and ten-day quadruple therapy with doxycycline might be an optional first-line therapy. The safety of regimens containing semisynthetic tetracyclines was relatively satisfactory. However, the triple regimen is not recommended.

Download full-text PDF

Source
http://dx.doi.org/10.1111/hel.12839DOI Listing

Publication Analysis

Top Keywords

quadruple therapy
12
therapy doxycycline
12
helicobacter pylori
8
systematic review
8
review meta-analysis
8
eradication rate
8
semisynthetic tetracycline
8
eradication rates
8
regimens semisynthetic
8
semisynthetic tetracyclines
8

Similar Publications

Experience of Metronidazole Triple Therapy After Clarithromycin Triple Therapy Failure for Eradication in Korea.

J Clin Med

December 2024

Department of Internal Medicine, Gyeongsang National University College of Medicine, Gyeongsang National University Hospital, Jinju 52727, Republic of Korea.

Bismuth quadruple therapy (BQT) is recommended as the best second-line regimen after failure of first-line clarithromycin triple therapy (CTT) for eradication. However, there are some limitations to this approach, including the lack of an appropriate sequel regimen after failure of BQT and complicated administration. Metronidazole triple therapy (MTT) is simple to administer, but it is not widely recommended.

View Article and Find Full Text PDF

GPLD1+ cancer stem cells contribute to chemotherapy resistance and tumor relapse in intestinal cancer.

J Biochem

January 2025

Laboratory of Anticancer Strategies, Advanced Research Initiative, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan.

Article Synopsis
  • Cancer stem cells (CSCs) are crucial in cancer growth and resistance, and recent research has identified GPLD1 as a marker for slowly cycling CSCs using a mouse intestinal cancer model.
  • Inhibiting GPLD1, particularly combined with the chemotherapy drug 5-fluorouracil, significantly reduces cancer cell viability and prevents tumor regrowth in organoids.
  • The study also reveals the role of GPLD1 in activating Wnt signaling and promoting epithelial-mesenchymal transition (EMT) through the cleavage of serine protease 8 (PRSS8), indicating that targeting GPLD1 could be a promising new treatment approach for colorectal cancer.
View Article and Find Full Text PDF

Characterizing Vericiguat Treatment in Heart Failure: A Multicenter Real-World Study in China.

Rev Cardiovasc Med

December 2024

Department of Cardiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, 230001 Hefei, Anhui, China.

Background: Real-world data on the clinical benefit of vericiguat are currently limited. This multicenter, real-world study was conducted to evaluate the clinical characteristics and therapeutic effects of vericiguat in real-world settings.

Methods: This study analyzed heart failure (HF) patients who initiated vericiguat treatment from September 2022 to August 2023 across nine hospitals in the Anhui Province, China.

View Article and Find Full Text PDF

Background: Helicobacter pylori infection is a major global health concern and has been associated with a number of gastrointestinal disorders. Probiotics, especially Lactobacillus spp., have been suggested to have beneficial effect in managing H.

View Article and Find Full Text PDF

Background: Multidrug, guideline-directed medical therapy (GDMT) improves mortality and hospitalizations for heart failure (HF), but little is known about how optimization of multidrug GDMT influences patient-reported outcomes. Trials of single GDMT medications demonstrate improvements in patient-reported outcomes; however, the effect of the multidrug GDMT regimen on patient-reported outcomes is unclear.

Objective: The objective of this study is to determine how multidrug optimization during a multidisciplinary, advanced practice provider HF clinic impacted patient-reported symptoms and quality of life in adults with HF.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!